Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

May 14, 2024

SELL
$1.09 - $20.4 $19,935 - $373,095
-18,289 Reduced 24.9%
55,148 $71,000
Q4 2022

Feb 13, 2023

SELL
$1.09 - $20.4 $19,935 - $373,095
-18,289 Reduced 24.9%
55,148 $71,000
Q3 2022

May 14, 2024

SELL
$1.7 - $20.52 $5,661 - $68,331
-3,330 Reduced 4.34%
73,437 $120,000
Q3 2022

Nov 10, 2022

SELL
$1.7 - $20.52 $5,661 - $68,331
-3,330 Reduced 4.34%
73,437 $0
Q2 2022

May 14, 2024

BUY
$1.35 - $2.29 $103,635 - $175,796
76,767 New
76,767 $161,000
Q2 2022

Aug 15, 2022

SELL
$1.35 - $2.29 $63,456 - $107,641
-47,005 Reduced 37.98%
76,767 $161,000
Q1 2022

May 16, 2022

BUY
$1.46 - $2.45 $99,880 - $167,606
68,411 Added 123.57%
123,772 $255,000
Q4 2021

Feb 14, 2022

SELL
$2.13 - $3.46 $161,892 - $262,980
-76,006 Reduced 57.86%
55,361 $129,000
Q3 2021

Nov 10, 2021

BUY
$3.14 - $3.9 $412,492 - $512,331
131,367 New
131,367 $457,000

Others Institutions Holding ASMB

# of Institutions
1
Shares Held
16.3K
Call Options Held
0
Put Options Held
0

About ASSEMBLY BIOSCIENCES, INC.


  • Ticker ASMB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,436,900
  • Market Cap $737M
  • Description
  • Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also deve...
More about ASMB
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.